 |
voretigene neparvovec-rzyl |
|---|---|
| Trade Name | Luxturna |
| Orphan Indication | Inherited retinal dystrophy due to biallelic RPE65 gene mutations |
| USA Market Approval | USA |
| USA Designation Date | 2015-03-18 00:00:00 |
| Sponsor | Spark Therapeutics, Inc.;3737 Market Street, Suite 1300;Philadelphia, Pennsylvania, 19104 |
